FetalFirst Registers Clinical Trial to Validate AI-Based Neonatal Risk Prediction
Study now live on ClinicalTrials.gov under NIH registration
London, United Kingdom – July 15, 2025 — FetalFirst Limited, a pioneering AI platform for fetal anomaly diagnostics and holistic parental support, has officially registered its first clinical trial with the U.S. National Library of Medicine (NIH), now publicly listed on ClinicalTrials.gov under the identifier NCT07064356
The study, titled “AI-Powered Neonatal Risk Assessment for Improved Perinatal Outcomes,” aims to validate FetalFirst’s ability to predict neonatal complications using advanced imaging, retrospective clinical documentation, and deep learning. By developing an explainable AI model, FetalFirst supports earlier, more informed medical decision-making and reduces uncertainty for families navigating complex diagnoses.
“Every parent deserves timely, unbiased, and clear information when facing a complex fetal diagnosis. This trial underscores our commitment to rigorous validation and global transparency, ensuring our technology earns the trust of both clinicians and families.”
The model has been trained on a large-scale, de-identified dataset across multiple institutions, leveraging advanced imaging and clinical documentation. FetalFirst’s technology stack integrates NVIDIA infrastructure and explainable AI methods, aligning with current standards in regulated medical AI.
Results from the study will be shared with NHS stakeholders and submitted for peer-reviewed publication, contributing to global research in perinatal care, ethical AI, and digital health innovation.
Key Facts
Trial Title: AI-Powered Neonatal Risk Assessment for Improved Perinatal Outcomes
Registry ID: NCT07064356
Sponsor: FetalFirst Ltd.
Study Type: Retrospective AI Validation
Website: www.fetalfirst.com
